nasopharyngeal carcinoma |
160 |
humans |
128 |
female |
91 |
male |
84 |
radiotherapy |
78 |
middle aged |
77 |
adult |
76 |
aged |
71 |
prognosis |
62 |
chemotherapy |
60 |
animals |
56 |
cancer |
54 |
medical sciences |
50 |
survival |
50 |
cell line, tumor |
49 |
neoplasm staging |
47 |
chinese |
46 |
oncology |
43 |
mice |
42 |
hepatocellular carcinoma |
41 |
epstein-barr virus |
40 |
metastasis |
39 |
aged, 80 and over |
38 |
chemoradiotherapy |
37 |
covid-19 |
37 |
quality of life |
37 |
treatment outcome |
36 |
gene expression regulation, neoplastic |
35 |
immunotherapy |
34 |
lung cancer |
34 |
esophageal squamous cell carcinoma |
33 |
dna methylation |
32 |
nasopharyngeal cancer |
32 |
gene expression profiling |
31 |
npc |
31 |
surgery |
31 |
targeted therapy |
31 |
breast cancer |
30 |
hong kong |
30 |
immunohistochemistry |
30 |
mice, nude |
30 |
reverse transcriptase polymerase chain reaction |
30 |
survival analysis |
30 |
biomarker |
29 |
disease-free survival |
29 |
follow-up studies |
29 |
tumor cells, cultured |
29 |
prognostic factors |
28 |
chromosome aberrations |
27 |
epidemiology |
27 |
esophageal cancer |
27 |
non-small cell lung cancer |
27 |
apoptosis |
26 |
transfection |
26 |
cisplatin |
25 |
genes, tumor suppressor |
25 |
in situ hybridization, fluorescence |
25 |
neoplasm metastasis |
25 |
nucleic acid hybridization |
25 |
survival rate |
25 |
adolescent |
24 |
antineoplastic combined chemotherapy protocols - therapeutic use |
24 |
efficacy |
24 |
lymphatic metastasis |
24 |
randomized controlled trial |
24 |
tumor suppressor gene |
24 |
whole-exome sequencing |
24 |
combined modality therapy |
23 |
gene amplification |
23 |
loss of heterozygosity |
23 |
methylation |
23 |
polymorphism, single nucleotide |
23 |
risk factors |
23 |
capecitabine |
22 |
colorectal cancer |
22 |
escc |
22 |
hcc |
22 |
chi-square distribution |
21 |
gastric cancer |
21 |
intensity-modulated radiotherapy |
21 |
promoter regions, genetic |
21 |
promoter regions, genetic - genetics |
21 |
radiotherapy dosage |
21 |
retrospective studies |
21 |
safety |
21 |
transplantation, heterologous |
21 |
tumor suppressor |
21 |
cell cycle |
20 |
chemotherapy, adjuvant |
20 |
china |
20 |
disease progression |
20 |
gene expression |
20 |
mutation |
20 |
nasopharyngeal neoplasms - genetics |
20 |
neoplasm transplantation |
20 |
polymerase chain reaction |
20 |
chemoresistance |
19 |
head and neck cancer |
19 |
imrt |
19 |
promoter hypermethylation |
19 |
signal transduction |
19 |
squamous cell carcinoma |
19 |
base sequence |
18 |
blotting, western |
18 |
cancer stem cells |
18 |
carcinoma |
18 |
immune checkpoint inhibitors |
18 |
incidence |
18 |
lymph nodes - pathology |
18 |
meta-analysis |
18 |
plasma ebv dna |
18 |
prognostication |
18 |
recurrence |
18 |
risk assessment |
18 |
treatment |
18 |
alleles |
17 |
carcinoma, squamous cell - genetics - metabolism - pathology |
17 |
cell proliferation |
17 |
ebv |
17 |
esophageal neoplasms - genetics - metabolism - pathology |
17 |
genomic instability |
17 |
late toxicity |
17 |
nasopharyngeal carcinoma (npc) |
17 |
neoplasm invasiveness |
17 |
oligonucleotide array sequence analysis |
17 |
prospective studies |
17 |
staging |
17 |
tumor microenvironment |
17 |
asian continental ancestry group |
16 |
china - epidemiology |
16 |
drug resistance, neoplasm |
16 |
e-cadherin |
16 |
emt |
16 |
genetic predisposition to disease |
16 |
intensity-modulated radiation therapy |
16 |
neoadjuvant therapy |
16 |
oesophageal squamous cell carcinoma |
16 |
prognostic marker |
16 |
reliability |
16 |
respiratory system - virology |
16 |
validity |
16 |
case-control studies |
15 |
cell differentiation |
15 |
chromosomes, human, pair 6 - genetics |
15 |
dce-mri |
15 |
epithelial-mesenchymal transition |
15 |
induction chemotherapy |
15 |
local recurrence |
15 |
molecular sequence data |
15 |
nomogram |
15 |
radiation |
15 |
young adult |
15 |
adc |
14 |
brachytherapy |
14 |
cancer survivors |
14 |
cells, cultured |
14 |
chromosome deletion |
14 |
chromosomes, human, pair 3 |
14 |
epigenetics |
14 |
esophageal carcinoma |
14 |
heterogeneity |
14 |
liquid biopsy |
14 |
magnetic resonance imaging |
14 |
mice, inbred balb c |
14 |
nasopharyngeal neoplasms - genetics - metabolism - pathology |
14 |
palliative care |
14 |
radiomics |
14 |
radiotherapy, adjuvant |
14 |
reirradiation |
14 |
reproducibility of results |
14 |
time factors |
14 |
tissue microarray |
14 |
toxicity |
14 |
tumor-initiating cells |
14 |
angiogenesis |
13 |
cadherins - metabolism |
13 |
cancer susceptibility genes |
13 |
carcinoma, squamous cell - genetics |
13 |
cell line |
13 |
cell line, transformed |
13 |
chromosome mapping |
13 |
chromosomes, human, pair 3 - genetics |
13 |
chromosomes, human, pair 9 - genetics |
13 |
conjunctiva - virology |
13 |
deep learning |
13 |
down-regulation |
13 |
early-age onset |
13 |
epstein–barr virus |
13 |
glycoproteins - metabolism |
13 |
hong kong - epidemiology |
13 |
invasion |
13 |
liver cancer |
13 |
mice, scid |
13 |
mst1r |
13 |
pet/ct |
13 |
prognostic factor |
13 |
radiology and nuclear medicine |
13 |
smoking |
13 |
t-lymphocytes, cytotoxic - immunology |
13 |
tissue array analysis |
13 |
toxicities |
13 |
tumor suppression |
13 |
virulence |
13 |
antineoplastic agents - pharmacology |
12 |
apobec-mediated signature |
12 |
biopsy |
12 |
bronchi - cytology |
12 |
cancer stemness |
12 |
cd133 |
12 |
cell division |
12 |
cell movement |
12 |
chronic diseases |
12 |
comparative genomic hybridization |
12 |
dna damage |
12 |
esophageal squamous cell carcinoma (escc) |
12 |
gamma rays |
12 |
genes, tumor suppressor - physiology |
12 |
health services |
12 |
influenza a virus, h1n1 subtype - metabolism |
12 |
influenza, human - virology |
12 |
liver neoplasms - metabolism - pathology |
12 |
microcell-mediated chromosome transfer |
12 |
microrna |
12 |
mind-body intervention |
12 |
nasopharyngeal neoplasms - radiotherapy |
12 |
neoplasm recurrence, local |
12 |
nf-κb signaling |
12 |
non-communicable diseases |
12 |
non-small-cell lung cancer |
12 |
overall survival |
12 |
phenotype |
12 |
public health |
12 |
radiation therapy |
12 |
responsiveness |
12 |
somatic mutation landscape |
12 |
stereotactic body radiation therapy |
12 |
survivorship |
12 |
systematic review |
12 |
treatment outcomes |
12 |
tumor stem cell assay |
12 |
tumor suppressor proteins - genetics - metabolism |
12 |
up-regulation |
12 |
xenograft model antitumor assays |
12 |
accelerated fractionation |
11 |
adult oncology |
11 |
analysis of variance |
11 |
apoptosis - drug effects |
11 |
cell transformation, neoplastic |
11 |
child |
11 |
chromosomes, human, pair 14 - genetics |
11 |
computed tomography |
11 |
dose fractionation |
11 |
dose-response relationship, drug |
11 |
dose-response relationship, radiation |
11 |
epidermal growth factor receptor |
11 |
esophagectomy |
11 |
intravoxel incoherent motion |
11 |
karyotyping |
11 |
liver regeneration |
11 |
measurement invariance |
11 |
microsatellite repeats |
11 |
nasopharyngeal neoplasms - genetics - pathology |
11 |
nasopharyngectomy |
11 |
next-generation sequencing |
11 |
nidogen-2 (nid2) |
11 |
phosphorylation |
11 |
precision oncology |
11 |
proteomics |
11 |
stereotactic body radiotherapy |
11 |
transcription, genetic |
11 |
tyrosine kinase inhibitor |
11 |
xerostomia |
11 |
adam proteins - genetics |
10 |
adamts9 |
10 |
adenocarcinoma |
10 |
age factors |
10 |
antiangiogenesis |
10 |
antigens, cd - genetics - metabolism |
10 |
antigens, cd - metabolism |
10 |
arhgap fusions |
10 |
asian continental ancestry group - genetics |
10 |
assessment |
10 |
biobank |
10 |
cancer progression |
10 |
carcinogenicity tests |
10 |
carcinoma - genetics |
10 |
case-control study |
10 |
cell movement - drug effects |
10 |
cell proliferation - drug effects |
10 |
chromosome segregation |
10 |
cognitive behavioral therapy |
10 |
cohort studies |
10 |
cross-sectional studies |
10 |
dna-binding proteins - genetics - metabolism |
10 |
dnmt1 |
10 |
down-regulation - drug effects |
10 |
drug screening |
10 |
ebv genome |
10 |
enzyme activation |
10 |
epithelial cells - drug effects - pathology |
10 |
esophageal neoplasms - genetics |
10 |
extracellular matrix protein |
10 |
family caregiver |
10 |
genetic markers |
10 |
in situ hybridization |
10 |
inflammation |
10 |
influenza a virus, h1n1 subtype - genetics - growth & development - pathogenicity |
10 |
influenza a virus, h1n2 subtype - genetics - growth & development - pathogenicity |
10 |
influenza a virus, h5n1 subtype - metabolism |
10 |
influenza, human - metabolism - transmission |
10 |
loh |
10 |
lung neoplasms - genetics |
10 |
microcell hybrid |
10 |
molecular sequence numbers |
10 |
molecular tumour board |
10 |
nasopharyngeal neoplasms |
10 |
neoplasm invasiveness - pathology |
10 |
nf-κb |
10 |
nucleic acid hybridization - methods |
10 |
oesophageal cancer |
10 |
organ culture techniques |
10 |
organoid culture |
10 |
peptides - metabolism |
10 |
radiation dose |
10 |
reassortant viruses - isolation & purification |
10 |
receptors, cell surface - metabolism |
10 |
recurrent |
10 |
respiratory mucosa - virology |
10 |
rhoa mutations |
10 |
salvage treatment |
10 |
screening |
10 |
sensitivity and specificity |
10 |
sequence-directed therapy |
10 |
sex factors |
10 |
spectrometry, mass, matrix-assisted laser desorption-ionization |
10 |
statistics, nonparametric |
10 |
survival prediction |
10 |
swine |
10 |
thy1 |
10 |
transarterial chemoembolization |
10 |
transcriptome sequencing |
10 |
viral tropism |
10 |
virus attachment |
10 |
xenograft |
10 |
25-hydroxyvitamin d |
9 |
adam proteins - biosynthesis - genetics - metabolism |
9 |
adverse events of special interest (aesi) |
9 |
allelic imbalance |
9 |
antineoplastic agents - therapeutic use |
9 |
arginine methylation |
9 |
biomarkers |
9 |
bnt162b2 |
9 |
breast neoplasms |
9 |
carcinoma, non-small-cell lung - enzymology - genetics - pathology |
9 |
carcinoma, squamous cell - epidemiology - genetics - pathology |
9 |
cell cycle arrest |
9 |
cell death - drug effects |
9 |
cell transformation, neoplastic - genetics |
9 |
chromatin accessibility |
9 |
chromosome 6p |
9 |
chromosomes, human, pair 11 |
9 |
chromosomes, human, pair 11 - genetics |
9 |
cognitive behavioural therapy |
9 |
coronavac |
9 |
cytology and histology |
9 |
cytotoxicity |
9 |
diagnosis |
9 |
dietary fiber |
9 |
dna |
9 |
dna - genetics |
9 |
drug resistance |
9 |
dual specificity phosphatase 6 - genetics - metabolism |
9 |
dual-specificity phosphatase 6 (dusp6) |
9 |
dw-mri |
9 |
electrophoresis, gel, two-dimensional |
9 |
endothelial cells - cytology |
9 |
esophageal neoplasms - blood supply - enzymology - genetics |
9 |
fact-c |
9 |
family caregivers |
9 |
flow cytometry |
9 |
fresh vegetable and fruit |
9 |
genetic epidemiology |
9 |
genetic susceptibility |
9 |
genetic variant |
9 |
genome-wide association study |
9 |
genotype |
9 |
herpesvirus 4, human - genetics |
9 |
host-virus interaction |
9 |
illumina humanmethylation450 |
9 |
immortalization |
9 |
intracellular signaling peptides and proteins - genetics - metabolism |
9 |
leucocyte telomere length |
9 |
life-course |
9 |
liver neoplasms - genetics - metabolism - pathology |
9 |
lung neoplasms - enzymology - genetics - pathology |
9 |
metastatic |
9 |
methylome |
9 |
microsatellite repeats - genetics |
9 |
milk |
9 |
mipol1 |
9 |
mrs |
9 |
multiple imputation |
9 |
multivariate analysis |
9 |
nasopharyngeal neoplasms - blood supply - enzymology - genetics |
9 |
neoadjuvant chemoradiotherapy |
9 |
nf-kappa b - metabolism |
9 |
npc risk |
9 |
nsclc |
9 |
nuclear proteins - genetics - metabolism |
9 |
oncology medical sciences |
9 |
outcomes |
9 |
preserved food |
9 |
rad51 recombinase |
9 |
radiology and nuclear medicine pharmacy and pharmacology biology |
9 |
recursive partitioning analysis |
9 |
rna, messenger - metabolism |
9 |
snp |
9 |
soybean product |
9 |
stage classification |
9 |
telomere biology |
9 |
tuberculosis reactivation |
9 |
tumor immune microenvironment |
9 |
tumor markers, biological - metabolism |
9 |
tumor suppressor proteins - genetics |
9 |
ultraviolet radiation |
9 |
vaccine |
9 |
vitamin d |
9 |
vitamin d deficiency |
9 |
whole-genome bisulfite sequencing |
9 |
adaptor proteins, signal transducing - physiology |
8 |
adenocarcinoma - genetics |
8 |
aging, premature - genetics |
8 |
bintrafusp alfa |
8 |
bone marrow cells - physiology - radiation effects |
8 |
brca1 protein - genetics |
8 |
cancer chemotherapy |
8 |
carcinoma - genetics - pathology |
8 |
carcinoma - radiotherapy |
8 |
carcinoma, hepatocellular - genetics - metabolism |
8 |
carcinoma, hepatocellular - metabolism - pathology |
8 |
carcinoma, hepatocellular - metabolism - pathology - secondary |
8 |
carcinoma, squamous cell - genetics - pathology |
8 |
carrier proteins - metabolism |
8 |
cell aging - genetics |
8 |
cell survival - drug effects - physiology |
8 |
cervical cancer |
8 |
checkpoint inhibitors |
8 |
chemokine cxcl1 - physiology |
8 |
child, preschool |
8 |
chromosomal proteins, non-histone |
8 |
cigarette smoking |
8 |
circulating neoplastic cell |
8 |
circulating tumor cells |
8 |
circulating tumor dna |
8 |
complications |
8 |
concurrent chemoradiotherapy |
8 |
concurrent chemotherapy |
8 |
correlative biomarkers |
8 |
cranial irradiation - adverse effects |
8 |
cyclin d1 - genetics - metabolism |
8 |
cytokines - genetics - physiology |
8 |
dna damage - genetics |
8 |
dna repair - physiology |
8 |
dna, neoplasm - genetics |
8 |
dose-response relation |
8 |
dosimetric predictors |
8 |
early detection |
8 |
epigenetic regulation |
8 |
etv4 |
8 |
fibroblasts - pathology - radiation effects |
8 |
frailty |
8 |
gastroenterology medical sciences |
8 |
genes, p53 |
8 |
genetics |
8 |
glycoproteins - deficiency - genetics - metabolism |
8 |
glycoproteins - genetics - metabolism |
8 |
head and neck cancers |
8 |
herpesvirus 4, human - immunology |
8 |
histones - genetics - metabolism - radiation effects |
8 |
hypothyroidism |
8 |
interleukin-8 - deficiency - genetics - physiology |
8 |
lamin type a - genetics - metabolism |
8 |
liver - metabolism - pathology - physiopathology |
8 |
liver neoplasms - genetics - metabolism |
8 |
lmp1 |
8 |
local control |
8 |
longitudinal real-time monitoring |
8 |
membrane proteins - genetics - metabolism |
8 |
metalloendopeptidases - genetics - metabolism |
8 |
metastatic colorectal cancer |
8 |
mice, mutant strains |
8 |
microarray analysis |
8 |
mortality |
8 |
neoplasm proteins - metabolism |
8 |
neoplasm staging - methods |
8 |
neovascularization, pathologic - genetics |
8 |
non-invasive biomarker |
8 |
non-metastatic |
8 |
nrp2 |
8 |
oesophagectomy |
8 |
ovarian cancer |
8 |
phosphoproteins - genetics - metabolism |
8 |
polymorphism, genetic - genetics |
8 |
positron emission tomography |
8 |
predictive value of tests |
8 |
prevalence |
8 |
protein precursors - genetics - metabolism |
8 |
radiation dosage |
8 |
recurrent or metastatic nasopharyngeal cancer |
8 |
rna interference |
8 |
rna‐seq |
8 |
saliva |
8 |
salivation - radiation effects |
8 |
second primary cancer |
8 |
sequence |
8 |
smoking cessation |
8 |
survival outcome |
8 |
telomerase |
8 |
telomere length |
8 |
transcription regulator |
8 |
tumor markers, biological |
8 |
tumor markers, biological - analysis |
8 |
tumor markers, biological - genetics - metabolism |
8 |
tumor suppressor proteins - metabolism |
8 |
tumorigenesis |
8 |
tyrosine kinase inhibitors |
8 |
unresectable |
8 |
-depression |
7 |
3p21 |
7 |
5-fluorouracil |
7 |
acupuncture |
7 |
advanced escc |
7 |
alpha b-crystallin (cryab) |
7 |
alpha-crystallin b chain - physiology |
7 |
anchor |
7 |
animal experiment |
7 |
animal model |
7 |
anti-angiogenic |
7 |
azygos vein blood |
7 |
blm |
7 |
breast neoplasms - epidemiology - genetics |
7 |
cancer incidence |
7 |
cancer-associated venous thrombosis (cat) |
7 |
cancer-related distress |
7 |
carcinoma, hepatocellular - drug therapy - physiopathology - secondary |
7 |
carcinoma, hepatocellular - metabolism |
7 |
carcinoma, non-small-cell lung - genetics |
7 |
carcinoma, squamous cell - genetics - pathology - secondary |
7 |
ccdc170 |
7 |
cell adhesion |
7 |
cell survival |
7 |
cell transformation, neoplastic - metabolism |
7 |
cell-free dna |
7 |
centromere |
7 |
centromere - drug effects - metabolism |
7 |
cetuximab |
7 |
chromatids - genetics - metabolism |
7 |
chromosomal instability - genetics |
7 |
chromosome 11q |
7 |
chromosomes, human - genetics |
7 |
chromosomes, human, pair 12 - genetics |
7 |
chromosomes, human, pair 17 |
7 |
circulating mirna |
7 |
circulating tumor cells (ctc) |
7 |
colorectal neoplasm |
7 |
controlled study |
7 |
cost-effectiveness |
7 |
cost-of-illness |
7 |
ctc clusters |
7 |
ctc enumeration |
7 |
cyclin b1 - genetics - metabolism |
7 |
defect |
7 |
delineation |
7 |
diagnosis and prognosis |
7 |
diffusion magnetic resonance imaging |
7 |
direct medical cost |
7 |
direct oral anticoagulants (doacs) |
7 |
distant metastases |
7 |
distress |
7 |
dna dsb repair |
7 |
dna primers |
7 |
dna probes |
7 |
early diagnosis |
7 |
early prediction |
7 |
egfr |
7 |
endothelial cells - drug effects |
7 |
enzyme-linked immunosorbent assay |
7 |
episome |
7 |
epithelial cells - metabolism - physiology |
7 |
epstein-barr virus infections - complications - genetics - metabolism - virology |
7 |
erk1/2 |
7 |
esophageal neoplasms - epidemiology - genetics - pathology |
7 |
familial npc |
7 |
fibulin-2 |
7 |
g 2 checkpoint |
7 |
g2 phase - genetics |
7 |
gene silencing |
7 |
genomic adjusted radiation dose |
7 |
graves’ disease |
7 |
hbv infection |
7 |
head and neck |
7 |
health care service provider |
7 |
health-related quality of life |
7 |
hepatitis b virus - genetics |
7 |
hepatitis b, chronic - genetics - immunology - metabolism |
7 |
herpesvirus 4, human - genetics - pathogenicity |
7 |
histone modifications |
7 |
histones - metabolism |
7 |
hypoxia |
7 |
hypoxia-inducible factor 1, alpha subunit - metabolism |
7 |
id‐1 |
7 |
ifnar1 |
7 |
illness perception |
7 |
image processing, computer-assisted |
7 |
immunoglobulins - deficiency - genetics - physiology |
7 |
inhibitor of differentiation protein 1 - antagonists & inhibitors - genetics - metabolism |
7 |
insomnia |
7 |
instability |
7 |
irradiation microcell-mediated chromosome transfer |
7 |
liver neoplasms - drug therapy - physiopathology - secondary |
7 |
liver transplantation |
7 |
long-term cancer survivors |
7 |
low-molecular-weight heparin (lmwh) |
7 |
lymph node metastasis |
7 |
lymphatic metastasis - genetics |
7 |
lymphopenia |
7 |
markov state-transition model |
7 |
membrane proteins - deficiency - genetics - physiology |
7 |
microarray analysis - methods |
7 |
microrna therapy |
7 |
migration |
7 |
mir‐338‐5p |
7 |
mitochondria |
7 |
mitosis |
7 |
mmp19 |
7 |
multidisciplinary |
7 |
mutations |
7 |
nasopharyngeal neoplasms - drug therapy - genetics - metabolism |
7 |
nasopharynx - metabolism - pathology - virology |
7 |
neoplasm invasiveness - genetics |
7 |
neoplasms |
7 |
neovascularization, pathologic - metabolism |
7 |
nhej |
7 |
nuclear proteins - metabolism |
7 |
nucleosome organization |
7 |
occupation |
7 |
oligodeoxyribonucleotides, antisense - pharmacology - therapeutic use |
7 |
outcome |
7 |
p21 |
7 |
p38 signaling |
7 |
p53 |
7 |
palliative |
7 |
parotid sparing |
7 |
pathway associations |
7 |
perfusion |
7 |
personalize |
7 |
pharyngectomy |
7 |
pilot projects |
7 |
precision medicine |
7 |
proteins - antagonists & inhibitors - genetics - metabolism |
7 |
quality-adjusted life years (qalys) |
7 |
questionnaires |
7 |
radiation injuries - complications |
7 |
radiosurgery |
7 |
rassf1a |
7 |
receptor, interferon alpha-beta - genetics |
7 |
reference values |
7 |
return to work |
7 |
sensorineural hearing loss |
7 |
service utilization |
7 |
sf-12 |
7 |
sleep disturbance |
7 |
sleep quality |
7 |
sleep trajectory |
7 |
spectral karyotyping |
7 |
stat5a |
7 |
statistics as topic |
7 |
structure-activity relationship |
7 |
telomerase - metabolism |
7 |
telomere |
7 |
tert |
7 |
therapeutics |
7 |
thyroid cancer |
7 |
tomography, x-ray computed |
7 |
transcription regulation |
7 |
transcriptional activation - physiology |
7 |
tumor burden |
7 |
tumor marker |
7 |
tumor markers, biological - blood |
7 |
tumor markers, biological - genetics |
7 |
twist transcription factor - metabolism |
7 |
vascular endothelial growth factor a - genetics - metabolism - secretion |
7 |
vegf |
7 |
viral persistence |
7 |
whole‐exome sequencing |
7 |
work productivity |
7 |
znf750 mutation |
7 |
β-catenin |
7 |
adaptive planning |
6 |
adaptor proteins, signal transducing - genetics - metabolism |
6 |
adherens junctions - metabolism |
6 |
adjuvant |
6 |
alpha b-crystallin |
6 |
amino acid sequence |
6 |
ampk |
6 |
androgen receptor |
6 |
animal tissue |
6 |
anti-angiogenesis |
6 |
antigens, differentiation - metabolism |
6 |
antigens, thy-1 - genetics - metabolism |
6 |
antigens, thy-1 - physiology |
6 |
antiinvasive |
6 |
apoptosis - genetics |
6 |
bq323636.1 |
6 |
cancer vaccine |
6 |
carcinoma - genetics - secondary |
6 |
carcinoma - metabolism - pathology |
6 |
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
carcinoma, squamous cell - metabolism - mortality |
6 |
carrier proteins - genetics |
6 |
cell separation |
6 |
cell signaling |
6 |
chemicals and cas registry numbers |
6 |
chromosome 11 |
6 |
chromosome 3, metastasis |
6 |
chromosomes, human, pair 1 - genetics |
6 |
chromosomes, human, pair 13 - genetics |
6 |
chromosomes, human, pair 8 |
6 |
confirmatory factor analysis |
6 |
conservation |
6 |
crip2 |
6 |
ctc |
6 |
cxcl8 |
6 |
cxcr2 |
6 |
cytokine |
6 |
decision-making |
6 |
deficit accumulation |
6 |
deoxycytidine - pharmacology |
6 |
dna damage repair pathway |
6 |
dna methylation - drug effects |
6 |
dna, neoplasm - analysis |
6 |
dna, viral - analysis |
6 |
dna, viral - isolation & purification |
6 |
dna-binding proteins - genetics |
6 |
dose escalation |
6 |
dosimetry |
6 |
economic evaluation |
6 |
economic evidence |
6 |
epstein−barr virus |
6 |
esophageal neoplasms - metabolism - mortality |
6 |
extranodal extension |
6 |
fatal outcome |
6 |
fluorescent antibody technique |
6 |
follow up |
6 |
frailty phenotype |
6 |
gene deletion |
6 |
gene expression regulation, neoplastic - drug effects |
6 |
gene expression regulation, neoplastic - physiology |
6 |
genes, cdc - physiology |
6 |
genome, human - genetics |
6 |
global health |
6 |
half-life clearance |
6 |
health care |
6 |
hepatocellular carcinomas |
6 |
histone bivalent switch |
6 |
human |
6 |
human leukocyte antigen |
6 |
hydroxamic acids - pharmacology |
6 |
hypermethylation |
6 |
immunoenzyme techniques |
6 |
invasiveness |
6 |
ivim |
6 |
latent tgf-beta binding proteins - genetics - metabolism |
6 |
latent transforming growth factor β binding protein 2 (ltbp-2) |
6 |
lim domain proteins - genetics - metabolism |
6 |
local clinical remission |
6 |
longitudinal studies |
6 |
ltbp-2 |
6 |
lung neoplasms |
6 |
m2 macrophages |
6 |
machine learning |
6 |
mastectomy, segmental |
6 |
matrix stiffness |
6 |
mechanoepigenetics |
6 |
medical records |
6 |
mental health |
6 |
metastatic growth |
6 |
mif |
6 |
mlh1 |
6 |
mode of administration |
6 |
molecular genetics |
6 |
ms‐hrm |
6 |
mtor |
6 |
muscle development |
6 |
nasopharyngeal neoplasms - metabolism - pathology |
6 |
nasopharynx |
6 |
neovascularization, pathologic |
6 |
nidogen-2 |
6 |
npc genetics |
6 |
older cancer patients |
6 |
oligo-microarray |
6 |
oncogene |
6 |
oral health |
6 |
oxaliplatin |
6 |
oxidative stress |
6 |
palbociclib |
6 |
palliative chemotherapy |
6 |
pancreatic neoplasms |
6 |
patient-derived xenografts |
6 |
pattern of failure |
6 |
pediatric |
6 |
pericardial effusion |
6 |
pi3k/akt |
6 |
plasma |
6 |
plasma epstein–barr virus deoxyribonucleic acid |
6 |
plasmids |
6 |
post-treatment plasma ebv dna |
6 |
postradiation malignancies |
6 |
prognostic predictor |
6 |
prostate cancer |
6 |
radiogenomic |
6 |
radiotherapy, intensity-modulated |
6 |
receptor-like protein tyrosine phosphatases, class 5 - genetics - physiology |
6 |
rhabdomyosarcoma |
6 |
saha |
6 |
salivary flow |
6 |
salvage therapy |
6 |
sbrt |
6 |
serum biomarker |
6 |
silibinin |
6 |
simulation models |
6 |
staging system |
6 |
stem cells - metabolism - pathology |
6 |
sulforaphane |
6 |
suv |
6 |
tamoxifen resistance |
6 |
tetracycline-regulated gene expression |
6 |
thbs2 |
6 |
thrombospondins - genetics - metabolism |
6 |
tnm staging |
6 |
tomography, x-ray computed - methods |
6 |
traditional chinese medicine |
6 |
translocation, genetic |
6 |
tumor cell dormancy |
6 |
tumor metastasis |
6 |
tumor staging |
6 |
tumor suppressor genes |
6 |
tumor suppressor protein p53 - biosynthesis - genetics |
6 |
tumour spheres |
6 |
twist1 |
6 |
wif1 |
6 |
2-methoxyestradiol |
5 |
3' untranslated region |
5 |
adenocarcinoma - drug therapy - economics |
5 |
adenoviridae - immunology |
5 |
adjuvant therapy |
5 |
aetiology |
5 |
aggressiveness |
5 |
aldehyde dehydrogenase - metabolism |
5 |
algorithms |
5 |
antibodies, monoclonal - diagnostic use |
5 |
antigen expression |
5 |
antigens, cd - biosynthesis - physiology |
5 |
antineoplastic agents |
5 |
antineoplastic agents, phytogenic - pharmacology |
5 |
antineoplastic combined chemotherapy protocols - administration and dosage - economics - therapeutic use |
5 |
antioncogenes. |
5 |
autoimmune disease |
5 |
biopsy, needle |
5 |
blotting, southern |
5 |
bmi-1 |
5 |
brain metastasis |
5 |
brca2 |
5 |
canagliflozin |
5 |
cancer immunosuppression |
5 |
cancer inhibition |
5 |
cancer outcomes |
5 |
cancer site-standardized relative survival |
5 |
cancer survival |
5 |
candidiasis, oral - classification |
5 |
carcinoma - blood - diagnosis - genetics |
5 |
carcinoma, hepatocellular - genetics - pathology |
5 |
carcinoma, non-small-cell lung - genetics - pathology |
5 |
carcinoma, squamous cell |
5 |
carcinoma, squamous cell - ethnology - metabolism - pathology |
5 |
carcinoma, squamous cell - genetics - metabolism |
5 |
carcinoma, squamous cell - mortality - pathology - therapy |
5 |
carrier proteins - genetics - physiology |
5 |
cell division - drug effects |
5 |
cell survival - drug effects |
5 |
cgh |
5 |
chemobrain |
5 |
cheung chau island |
5 |
childhood lymphoma |
5 |
chromosome 3 |
5 |
chromosomes, human, pair 10 - genetics |
5 |
chromosomes, human, pair 20 |
5 |
chromosomes, human, pair 3 - ultrastructure |
5 |
chromosomes, human, pair 5 - genetics |
5 |
cisplatin - pharmacology |
5 |
clone cells |
5 |
cluster analysis |
5 |
colorectal neoplasms - drug therapy - economics |
5 |
ct |
5 |
cyclin d1 |
5 |
cyclin e |
5 |
cytokines - blood - genetics - metabolism |
5 |
dapagliflozin |
5 |
dental caries |
5 |
dental caries - classification |
5 |
diagnosis, differential |
5 |
diet |
5 |
differentiation |
5 |
diffusion weighted imaging |
5 |
diffusion-weighted imaging |
5 |
dmf index |
5 |
dna - metabolism |
5 |
dna mutational analysis |
5 |
dna, complementary - genetics |
5 |
dna, viral - blood |
5 |
dna-binding proteins - metabolism |
5 |
docetaxel |
5 |
double-negative b cells |
5 |
drug repurposing |
5 |
drug resistance, neoplasm - physiology |
5 |
ductal carcinoma in situ |
5 |
ebv‐encoded small rna |
5 |
elderly |
5 |
endoreduplication |
5 |
enox2 |
5 |
epithelial cells - cytology |
5 |
epstein-barr virus infections - immunology - therapy |
5 |
epstein-barr virus nuclear antigens - immunology |
5 |
epstein–barr virus infection |
5 |
eq-5d-5 l |
5 |
ercc1 |
5 |
esophageal cancer surgery |
5 |
esophageal cancer susceptibility gene |
5 |
esophageal neoplasms - ethnology - metabolism - pathology |
5 |
esophageal neoplasms - genetics - metabolism |
5 |
esophageal neoplasms - mortality - pathology - therapy |
5 |
exosomes |
5 |
fascin |
5 |
fluorescence in situ hybridization |
5 |
folinic acid |
5 |
functional assessment |
5 |
gastroenterology |
5 |
gefitinib |
5 |
gene dosage |
5 |
gene expression regulation, neoplastic - genetics |
5 |
genome‐wide analysis |
5 |
gist |
5 |
glycoproteins - biosynthesis - physiology |
5 |
grp78 |
5 |
guideline |
5 |
health care costs - statistics and numerical data |
5 |
health economics |
5 |
health status indicators |
5 |
her2+ breast cancer |
5 |
her2-targeted therapy |
5 |
hospital authority |
5 |
hybrid cells |
5 |
icg-001 |
5 |
idronoxil |
5 |
igra |
5 |
illness perceptions |
5 |
immune checkpoint inhibitor |
5 |
immunization, passive |
5 |
income |
5 |
infant |
5 |
insurance, health, reimbursement - economics |
5 |
intensity-modulated |
5 |
invadopodia |
5 |
kinetics |
5 |
latent membrane protein 1 |
5 |
live-cell imaging |
5 |
liver metastases |
5 |
liver neoplasms - drug therapy - enzymology |
5 |
liver neoplasms - genetics - pathology |
5 |
local failure |
5 |
loss‐of‐function mutations |
5 |
lung |
5 |
lymphoma |
5 |
lymphomas-- genetic aspects. |
5 |
mandible - pathology - radiation effects - surgery |
5 |
map kinase signaling system - drug effects - physiology |
5 |
medically inoperable |
5 |
memory t-cells |
5 |
metastatic brain tumours |
5 |
metronomic |
5 |
microfilament proteins - genetics |
5 |
mild cognitive impairment |
5 |
mouth diseases - classification |
5 |
mouth neoplasms - genetics - pathology |
5 |
multidisciplinary management |
5 |
nasopharyngeal neoplasms - blood - diagnosis - genetics |
5 |
nasopharyngeal neoplasms - complications - radiotherapy |
5 |
nasopharyngeal neoplasms - drug therapy - genetics - pathology |
5 |
nasopharyngeal neoplasms - drug therapy - mortality - pathology - radiotherapy |
5 |
nasopharyngeal neoplasms - drug therapy - mortality - radiotherapy |
5 |